Cost-Effectiveness Analysis of Cerebrolysin In The Treatment of Patients With Acute Ischemic Stroke Moderate and Severe Degrees of Severity In The Russian Federation

Kulikov, A.Yu.; Abdrashitova, G.T.

doi:10.1016/j.jval.2015.09.2645

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kulikov and Abdrashitova et al aimed to evaluate the cost effectiveness of Cerebrolysin against standard therapy for patients diagnosed with moderate or severe stroke. Based on the reported results, Cerebrolysin was the dominant therapy, as cost-effectiveness ratios (CER) were lower (EUR 6920) than standard therapy (EUR 9287) [ 55 ]. Kulikov and Abdrashitova et al have also been developing a complementary budget impact analysis (BIA) since 2015, which showed that Cerebrolysin has lower direct costs associated with medical care (inpatient and outpatient care, pharmacotherapy, emergency care and neurorehabilitation) and indirect costs (loss of productivity caused by sick leave, disability, and death).…”

Section: Cost-effectiveness Researchmentioning

confidence: 99%

“…While existing studies are scarce, there is a signal that Cerebrolysin is probably cost-effective, with the potential to reduce the economic burden on national budgets, both as standard treatments in patients with different levels of severity [ 55 , 56 ] or in combination with another pharmacological therapy (i.e., alteplase) [ 57 ] in countries with different types of health insurance [ 58 , 59 ].…”

Section: Cost-effectiveness Researchmentioning

confidence: 99%

See 1 more Smart Citation

Role and Impact of Cerebrolysin for Ischemic Stroke Care

Mureșanu

Popa

Chira

et al. 2022

JCM

View full text Add to dashboard Cite

Stroke is still a significant health problem that affects millions of people worldwide, as it is the second-leading cause of death and the third-leading cause of disability. Many changes have occurred in the treatment of acute ischemic stroke. Although the innovative concepts of neuroprotection and neurorecovery have been vigorously investigated in a substantial number of clinical studies in the past, only a few trials managed to increase the number of promising outcomes with regard to the multidimensional construct of brain protection and rehabilitation. In terms of pharmacological therapies with proven benefits in the post-ischemic process, drugs with neurorestorative properties are thought to be effective in both the acute and chronic phases of stroke. One significant example is Cerebrolysin, a combination of amino acids and peptides that mimic the biological functions of neurotrophic factors, which has been shown to improve outcomes after ischemic stroke, while preserving a promising safety profile. The purpose of this paper is to offer an overview on the role and impact of Cerebrolysin for ischemic stroke care, by touching on various aspects, from its complex, multimodal and pleiotropic mechanism of action, to its efficacy and safety, as well as cost effectiveness.

show abstract

Section: Cost-effectiveness Researchmentioning

confidence: 99%

Section: Cost-effectiveness Researchmentioning

confidence: 99%

Role and Impact of Cerebrolysin for Ischemic Stroke Care

Mureșanu

Popa

Chira

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Current findings also suggested that the effect of CH on neuroplasticity and nerve recovery was greater than that on neuroprotection, and might have the greatest impact in the rehabilitation stage (Mureșanu et al, 2022). In addition, there was a signal that CH had the potential to significantly reduce the economic burden of the national budget, which could be used as the standard treatment for patients with different severity, or combined with another drug treatment (Kulikov and Abdrashitova, 2015;Walter et al, 2015). In 2021, the guidelines of the European Academy of Neurology and European Federation of Neurorehabilitation Societies on drug support for early exercise rehabilitation after acute ischemic stroke recommended the use of two drugs, namely, CH and citalopram (Beghi et al, 2021;Mureșanu et al, 2022).…”

Section: Introductionmentioning

confidence: 95%

Identification and Validation of Active Ingredient in Cerebrotein Hydrolysate-I Based on Pharmacokinetic and Pharmacodynamic Studies

Guo,

Yang,

et al. 2023

Drug Metab Dispos

View full text Add to dashboard Cite

Cerebrotein hydrolysate-1 (CH-1), a mixture of small peptides, polypeptides and various amino acids derived from porcine brain, has been widely used in the treatment of cerebral injury. However, the bioactive composition and pharmacokinetics of CH-1 are still unexplored because of their complicated composition and relatively tiny amounts in vivo.Herein, NanoLC-Orbitrap-Fusion-Lumos-Tribrid-MS/MS was firstly used to qualitatively analyze the components of CH-1. A total of 1347 peptides were identified, of which 43 peptides were characterized by high MS intensity and identification accuracy. We then innovatively synthesized 4 main peptides for activity verification, and the results suggested that Pep72 (NYEPPTVVPGGDL) had the strongest neuroprotective effect on both in vivo and in vitro models. Next, a quantitative method for Pep72 was established based on LC-MS/MS with the aid of Skyline software, and then used in its pharmacokinetic studies. The results revealed that Pep72 had a high elimination rate and low exposure in rats. In addition, hCMEC/D3 based in vitro model was built and firstly used to investigate the transport of Pep72. We found that Pep72 had extremely low blood-brain barrier (BBB) permeability, and was not a substrate of efflux transporters. The biotransformation of Pep72 in rat fresh plasma and tissues was investigated to explore the contradiction between pharmacokinetics and efficacy. A total of 11 main metabolites were structurally identified, with PGGDL and EPPTVPGGDL being the main metabolites of Pep72. Notably, metalloproteinase and cysteine protease were confirmed to be the main enzymes mediating Pep72 metabolism in rat tissues.

show abstract

“…croglial activation/neuroinflammation [12][13][14][15]. Additionally, it has been demonstrated to exhibit neurotrophic activity, promote neuronal sprouting, improve cellular survival and stimulate neurogenesis [16][17][18].…”

Section: Conclusion In Conclusion It Was Found That Pretreatment Withmentioning

confidence: 99%

Attenuation of Morphine-Induced Tolerance and Dependence by Pretreatment with Cerebrolysin in Male rats

Ghavimi¹,

Darvishi²,

Ghanbarzadeh

2017

Drug Res (Stuttg)

View full text Add to dashboard Cite

show abstract

Cost-Effectiveness Analysis of Cerebrolysin In The Treatment of Patients With Acute Ischemic Stroke Moderate and Severe Degrees of Severity In The Russian Federation

Cited by 4 publications

References 0 publications

Role and Impact of Cerebrolysin for Ischemic Stroke Care

Role and Impact of Cerebrolysin for Ischemic Stroke Care

Identification and Validation of Active Ingredient in Cerebrotein Hydrolysate-I Based on Pharmacokinetic and Pharmacodynamic Studies

Attenuation of Morphine-Induced Tolerance and Dependence by Pretreatment with Cerebrolysin in Male rats

Contact Info

Product

Resources

About